Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Body mass index (BMI) of 18 to 38 kilogram/square meter (kg/m\^2) and weight \>= 40 kg at screening
Documented physician-diagnosed asthma
On high dose inhaled corticosteroid (ICS) therapy plus at least one additional allowed controller medication
Forced expiratory volume in 1 second (FEV1) of 40% to 80% of predicted
Evidence of uncontrolled asthma
Use of contraceptive measures
You may not be if
Diagnosis of mimics of asthma
Diagnosis of occupational asthma, aspirin-sensitive asthma, asthma chronic obstructive pulmonary disease overlap syndrome, or bronchiolitis, as determined by the investigator
Pregnant or lactating, or intending to become pregnant during the study or within 20 weeks after the last dose of MSTT1041A
Recent history of smoking
History or evidence of substance abuse that would pose a risk to participants safety, interfere with the conduct of the study, have an impact on the study results
Asthma exacerbation within 4 weeks prior to screening
Intubation for respiratory failure due to asthma within 12 months prior to screening
Comorbid conditions that may interfere with evaluation of investigational medicinal product
Known sensitivity to any of the active substances or their excipients to be administered during dosing
Positive pregnancy test
Clareo Health | A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Uncontrolled Severe Asthma
